Robert Blouin
Document Actions
Publications
1. Westerfield BT, Blouin RA: Ethchlorvynol intoxication. South Med J. 70:1019-1020, 1977.
2. Bivens BA, Rapp RP, Griffen WO Jr., Blouin RA, Bustrack JA: Dopamine - phenytoin interaction. Arch Surg 113:245-249, 1978.
3. Rapp RP, Bustrack JA, Blouin RA: Dopamine interaction. Drug Intell Clin Pharm 12:249, 1978.
4. Blouin RA, Mann HJ, Griffen WO Jr., Bauer LA, Record KE: Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 26:508-512, 1979.
5. Bauer LA, Blouin RA, Griffen WO Jr., Record KE, Bell RM: Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 37:519-522, 1980.
6. Blouin RA, Bauer LA, Piecoro JJ, Holland NH: Decreased gentamicin half-life during peritoneal dialysis: A case report. Drug Intell Clin Pharm 14:218-219, 1980.
7. Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivens BA: Theophylline hemodialysis clearance. Ther Drug Monit 2:221-223, 1980.
8. Blouin RA, Elgert JF, Bauer LA: Theophylline clearance: effect of marked obesity. Clin Pharmacol Ther 28:619-623, 1980.
9. Blouin RA, Erwin WG, Dutro MP, Bustrack JA, Rowse KL: Chloramphenicol hemodialysis clearance. Ther Drug Monitor 2:351-354, 1980.
10. Oeltgen PR, Hamann SR, Blouin RA: Comparison of gentamicin assays. Ther Drug Monit 2:423-425, 1980.
11. Bauer LA, Blouin RA: Influence of age on theophylline clearance in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet 6:469-474, 1981.
12. Dionne RE, Bauer LA, Gibson GA, Griffen WO Jr., Blouin RA: Estimating creatinine clearance in morbidly obese patients. Am J Hosp Pharm 38:841-844, 1981.
13. Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB: Phenytoin-dexamethazone interaction: a previously unreported observation. Surg Neurol 16:23-24, 1981.
14. Bailey RT, Young AB, Rapp RP, Blouin RA: Theophylline toxicity after the use of aminophylline in the treatment of cerebral vasospasm. Neurosurgery 9:722-724, 1981.
15. Bauer LA, Blouin RA: Influence of age on tobramycin pharmacokinetics in patients with normal renal function. Antimicrob Agents Chemother 20:587-589, 1981.
16. Bauer LA, Bauer SP, Blouin RA: The effect of acute and chronic renal failure on theophylline clearance. J Clin Pharmacol 22:65-68, 1982.
17. Lawson LA, Blouin RA, Parker PF: Quality assurance program for a clinical pharmacokinetic service. Am J Hosp Pharm 39:607-609, 1982.
18. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr.,: Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 21:575-580, 1982.
19. Blouin RA, Erwin WG, Foster TS, Scott S: Pharmacokinetics of theophylline in young and elderly subjects. Gerontology 28:323-327, 1982.
20. Hamann SR, Oeltgen PR, Shank WA, Blouin RA, Natarajan L: Evaluation of gentamicin pharmacokinetics during peritoneal dialysis. Ther Drug Monitor 4:297-300, 1982.
21. Bauer LA, Blouin RA: Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 31:301-304, 1982.
22. Bauer LA, Blouin RA: Gentamicin pharmacokinetics: Effect of aging in patients with normal renal function. J Am Geriatr Soc 30:309-311, 1982.
23. Bauer LA, Blouin RA: Amikacin pharmacokinetics in young men with pneumonia. Clin Pharm 1:353-355, 1982.
24. Bauer LA, Piecoro JJ, Wilson HD, Blouin RA: Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clin Pharm 2:262-264, 1983.
25. Bauer LA, Blouin RA: Influence of age on amikacin pharmacokinetics in patients without renal disease: Comparison with gentamicin and tobramycin. Eur J Clin Pharmacol 24:639-642, 1983.
26. Benedek IH, Fiske WD, Griffen WO Jr., Bell RM, ,Blouin RA, McNamara PJ: Serum alpha-1 acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 16:751-754, 1983.
27. Bauer LA, Blouin RA: Phenytoin Michaelis-Menton pharmacokinetics in Caucasian paediatric patients. Clin Pharmacokinet 8:545-549, 1983.
28. Hamann SR, Blouin RA, McAllister RG: Clinical pharmacokinetics of verapamil. Clin Pharmacokinet 9:26-41, 1984.
29. Benedek IH, Blouin RA, McNamara PJ: Influence of smoking on serum protein composition and the protein binding of drugs. J Pharm Pharmacol 36:214-216, 1984.
30. Bauer LA, Edwards WA, Randolph FP, Blouin RA: Cimetidine induced decreases in lidocaine metabolism. Am Heart J 108:413-415, 1984.
31. Oeltgen PR, Shank WA, Blouin RA, Clark T: Clinical evaluation of the Abbott TDx(TM) fluorescence polarization immunoassay analyzer. Ther Drug Monit 6:360-367, 1984.
32. O'Neal W, Whitten KM, Baumann RJ, Blouin RA, Piecoro JJ: Lack of serious toxicity following carbamazepine overdose. Clin Pharm 3:545-547, 1984.
33. Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RA: Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. J Pharmacol Exp Ther 231:649-653, 1984.
34. Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RB: Phenobarbital in the genetically obese Zucker rat. II. In Vivo and In Vitro assessments of microsomal enzyme induction. J Pharmacol Exp Ther 231:654-659, 1984.
35. Benedek IH, Blouin RA, McNamara PJ: Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 18:941-946, 1984.
36. Hamann SR, Blouin RA, Chang SL, Kaltenborn KE, Tan TG, McAllister RG: Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine. J Pharmacol Exp Ther 231:301-305, 1984.
37. Blouin RA, Brouwer KL, Record KE, Griffen WO Jr., Plezia PM, John W: Amikacin pharmacokinetics in morbidly obese patients undergoing gastric by-pass surgery. Clin Pharm 4:70-72, 1985.
38. Hamann SR, Tan TG, Kaltenborn KE, Brouwer KLR, Blouin RA, Chang SL, Vore M, McAllister RG: Effects of phenobarbital and SKF-525A on In Vitro hepatic metabolism of verapamil and nifedipine. Pharmacology 30:121-128, 1985.
39. Oeltgen PR, Blouin RA, Spurrier WA, Myers RD: Hibernation "Trigger" alters renal function in the primate. Physiol Behav 34:79-81, 1985.
40. McAllister RG, Hamann SR, Blouin RA: Pharmacokinetics of calcium entry blockers. Am J Cardiol 55:30B-40B, 1985.
41. Gibson GA, Blouin RA, Bauer LA, Rapp RP, Tibbs PA: Influence of high dose pentobarbital on theophylline pharmacokinetics: a case report. Ther Drug Monitor 7:181-184, 1985.
42. Benedek IH, Blouin RA, McNamara PJ: Altered drug-serum protein binding in the genetically obese Zucker rat. J Pharm Sci 74:837-840, 1985.
43. Wermeling D, Record K, Bell R, Porter W, Blouin RA: Hemodialysis clearance of pentobarbital during continuous infusion: A case report. Ther Drug Monit 7:485-487, 1985.
44. Michael KA, Mohler JL, Blouin RA, Lucas BA, Rapp RP: Failure of creatinine clearance to predict gentamicin half-life in a renal transplant patient with diabetes mellitus. Clin Pharm 4:572-575, 1985.
45. Mohler JL, Barton SD, Blouin RA, Cowen DL, Flanigan RC: The evaluation of creatinine clearance in spinal cord injured patients. J Urology 136:366-369, 1986.
46. Fiske WD, Blouin RA, Mitchell B, McNamara PJ: Renal function in the obese Zucker rat. Int J Obes 10:175-183, 1986.
47. Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA: Pentobarbital pharmacokinetics in patients with severe head injury. Drug Intell Clin Pharm 21:459-463, 1987.
48. Huang Chandler MH, Guttendorf RJ, Blouin RA, Wedlund PJ: Simultaneous quantitation of d- and l-hexobarbital in rat blood by HPLC. J Chromatogr 419: 426-432, 1987.
49. Blouin RA, Kolpek JH, Mann HJ: Influence of obesity on drug disposition. Clin Pharm 6:706-714, 1987.
50. Blouin RA, Dickson P, McNamara PJ, Cibull M, McClain C: Phenobarbital induction and acetaminophen hepatotoxicity: resistance in the obese Zucker rodent. J Pharmacol Exp Ther 243:565-570, 1987.
51. Clifton GD, Blouin RA, Dilea C, Schran HF, Hassell AE, Gonasun LM, Foster TS: The pharmacokinetics of oral isradipine in normal volunteers. J Clin Pharmacol 28:36-42, 1988.
52. Chandler MH, Scott SR, Blouin RA: Age-associated stereoselective alterations in hexobarbital metabolism. Clin Pharmacol Ther 43:436-441, 1988.
53. McNamara PJ, Blouin RA, Brazzell RK: The protein binding of phenytoin, propranolol, diazepam and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res 5:261-265, 1988.
54. McNamara PJ, Blouin RA, Brazzell RK: Serum protein binding of AL01576, a new aldose reductase inhibitor. Pharm Res 5:319-321, 1988.
55. Chandler MH, Blouin RA: Theophylline pharmacokinetics in the aged: A review. J Geriatric Drug Ther 3:23-40, 1988.
56. Chandler MH, Schran HF, Cutler RE, Smith AJ, Gonasun LM, Blouin RA: The effects of renal function on the disposition of isradipine. J Clin Pharmacol 28:1076-1080, 1988.
57. Heintz RC, Ducarre JM, Blouin RA, Guengi A: Influence of oral dose escalation on the pharmacokinetics of tenoxicam [Tilcotil] in healthy male subjects. Eur J Rheum Inflam 9-15, 1988.
58. Colangelo P, Chandler M, Blouin R, McNamara P: Stereoselective binding of propranolol. Br J Clin Pharmacol 27:519-522, 1989.
59. Blouin RA, Kneer J, Stoeckel K: Pharmacokinetics of cefetamet (RO15-8074) and oral sefetamet pivoxil (RO15-8075) in young and elderly subjects. Antimicrob Ag Chemoth 33:291-296, 1989.
60. Foster TS, Kielar RA, Blouin RA, Parr MD, Barton S, Perchak GJ, Johnson JB: Maintenance of previously controlled intraocular pressure in patients with glaucoma or ocular hypertension: Comparison of four regimens of methazolamide. Glaucoma 11:67-71, 1989.
61. Blouin RA, Clifton GD, Adams MA, Foster TS, Flueck J: Biopharmaceutical comparison of two levothyroxine sodium products. Clin Pharm 8:588-592, 1989.
62. Kneer J, Tam YK, Blouin RA, Frey FJ, Keller E, Stathakis C, Luginbuehl B, Stoeckel K: Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother 33:1952-1957, 1989.
63. Hatton J. Parr MD, Blouin RA: Estimation of creatinine clearance in patients with Cushing's Syndrome. Drug Intell Clin Pharm 23:974-976, 1989.
64. Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA, Wedlund PJ: Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol 29:373-380, 1990.
65. McNamara PJ, Blouin RA: Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rats. J Pharm Sci 79:301-304, 1990.
66. Chandler MH, Clifton GD, Burki NK, Hunt BA, Blouin RA: Pulmonary function in the elderly: response to theophylline bronchodilation. J Clin Pharmacol 30:330-335, 1990.
67. Hayton WL, Kneer J, Blouin RA, Stoeckel K: Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis. Antimicrob Agents Chemoth 34:1318-1322, 1990.
68. Schoerlin MP, Blouin RA, Pfefen JP, Guentert TW: Comparison of the pharmacokinetics of moclobemide in poor and extensive metabolizers of debrisoquine. Acta Psychiatr Scand Suppl 360:98-100, 1990.
69. Blouin RA, Kneer J, Ambrose RJ, Stoeckel K: Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil. Antimicrob Agents Chemoth 34:1744-1748, 1990.
70. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ: Limitation to the use of the urinary S/R mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 31:350-352, 1991.
71. Colangelo P, Rapp R, Blouin R and Kenady D: Comparative bioavailability and safety of two parenteral vancomycin formulations. J N Dev Clin Med 8:11-20, 1991.
72. Blouin RA, Cloyd JC, Ludden TM, Kroboth PD: Central issues relevant to clinical pharmaceutical scientist training programs. Pharmacotherapy 11:257-263, 1991.
73. Smith DA, Chandler MH, Shedlofsky SI, Wedlund PJ, Blouin RA: Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampin. Br J Clin Pharmacol 32:735-39, 1991.
74. Blouin RA, Hamelin BA, Smith DA, Foster TS, John WJ, Welker HA: Fleroxacin pharmacokinetics in patients with liver cirrhosis. Antimicrob Ag Chemoth 36:632-638, 1992.
75. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Demaria AN, Wedlund PJ: Age and propranolol stereoselective disposition in humans. Clin Pharmacol Ther 51:489-494, 1992.
76. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Demaria AN, Wedlund PJ: Age and beta-adrenergic receptor sensitivity to S(-)- and R,S(+/-)-propranolol in humans. Clin Pharmacol Ther 51:549-554, 1992.
77. Hamelin BA, Blouin RA, Wolf KM, Clifton GD, Chandler MH: In vivo and in vitro beta-2 adrenergic receptor responsiveness in young and elderly asthmatics. Pharmacotherapy 12:376-382, 1992.
78. Blouin RA, Chaudhary I, Nishihara K, Cox SA: The effect of liver and renal disease on stereoselective serum binding of flurbiprofen. Br J Clin Pharmacol 35:62-64, 1993.
79. Blouin RA: Issues in pharmacotherapy: Hepatic cytochrome P450 - Application of animal models to therapeutic problems in humans. The ACCP Report 13:(2),1993.
80. Israel BC, Blouin RA, McIntyre W, Shedlofsky SI: Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 36:229-235, 1993.
81. Blouin RA, Bandyopadhyay AM, Chaudhary I, Robertson LW, Gemzik B, Parkinson A: Cytochrome P450 2B enzyme (CYP2B) induction defect following phenobarbital treatment in the fa/fa rat: Molecular characterization. Arch Biochem Biophys 303:313-320, 1993.
82. Chaudhary I, Tuntaterdtum S, McNamara PJ, Robertson LW, Blouin RA: Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways. J. Pharmacol. Exp. Ther 265:1333-1338, 1993.
83. Blouin RA, Stoeckel K: Cefetamet pivoxil clinical pharmacokinetics. Clin.Pharmacokinet 25:172-188, 1993.
84. Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA: Effect of nutritional obesity on the induction of CYP2B enzymes following phenobarbital treatment. Drug Metab Dispos 21:782-787, 1993
85. Toler SM, Young B, McClain CJ, Shedlofsky SI, Bandyopadhyay AM, Blouin RA: Head injury and cytochrome P-450 enzymes. Differential effects on mRNA and protein expression in the Fischer-344 rats. Drug Metab Dispos 21:1064-1069, 1993.
86. Bandyopadhyay AM, Chaudhary I, Robertson LW, Gemzik B, Parkinson A, Blouin RA: Expression of a male-specific cytochrome P450 isozyme (CYP2C11) in fa/fa Zucker rats: effect of phenobarbital treatment. Arch Biochem Biophys 307:386-390, 1993.
87. Tuntaterdtum S, Chaudhary I, Cibull ML, Robertson LA, Blouin RA: Acetaminophen hepatotoxicity: influence of phenobarbital and ß-naphthoflavone treatment in obese and lean Zucker rats. Toxicol Appl Pharmacol 123:219-225, 1993.
88. Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA: Expression of the CYP3A and CYP2C11 enzymes in a nutritionally obese rodent model: response to phenobarbital treatment. Int J Obes Relat Metab Disord 18:369-374, 1994.
89. Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA: Cytochrome P450 2B enzyme induction defect after 2,2’,4,4’,5,5’-hexachlorobiphenyl treatment in the fa/fa Zucker rat. J Pharmacol Exp Ther 268:1565-1570, 1994.
90. Blouin RA, McNamara PJ, Chandler MHH, Kostenbauder HB: Development of a clinical pharmacology program at the University of Kentucky College of Pharmacy. Am J Pharm Educ 58:289-293, 1994.
91. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA: Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 94:2209-2214, 1994.
92. Chen S, Chou W, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ: The cytochrome P450-2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522-534, 1996.
93. Roe AL, Blouin RA, Howard G: In vivo phenobarbital treatment increases protein binding to a putitive AP-1 site in the CYP2B2 promoter. Biochem Biophys Res Commun 228:110-114, 1996.
94. Shedlofsky SI, Israel BC, Tosheva R, Blouin RA: Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol 43:627-632, 1997.
95. Rees WA, Harkins JD, Woods WE, Blouin RA, Lu M, Fenger C, Holland RE, Chambers TM, Tobin T: Amantadine and equine influenza: Pharmacology, pharmacokinetics, and neurological effects in the horse. Equine Vet J 29(2):104-110, 1997.
96 Roe AL, Howard G, Hou G, Howard G, Shedlofsky S, Blouin RA: The effect of high dose endotoxin on CYP3A2 expression in the rat. Pharm Res 15:1603-1608, 1998.
97. Stoeckel K, Hofheinz W, Laneury JP, Duchene P, Shedlofsky SI, Blouin RA: Stability of cephalosporin prodrug esters in human intestinal juice: Implications for oral bioavailability. Antimicrob Agents Chemother 42:2602-2606, 1998.
98. Roe AL, Howard G, Blouin RA: Characterization of nuclear protein binding (AP-1, GR, and STAT) in the genetically obese (fa/fa) Zucker rat. Life Sci 63:1339-1346, 1998.
99. Blouin RA, Warren GW: Pharmacokinetic considerations in obesity. J. Pharm. Sci 88:1-7, 1999.
100. Roe AL, Howard G, Blouin RA, Snawder JE: Characterization of cytochrome P450 and glutatione S-transferase activity and expression in male and female ob/ob mice. Int. J. Obesity 23:48-53, 1999.
101. Watson AM, Warren G, Howard G, Shedlofsky SI, Blouin RA: Activities of conjugating and antioxidant enzymes following endotoxin exposure. J Biochem Mol Toxicol 13:63-69, 1999.
102. Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA: Hepatic cytochrome P-450 expression in the tumor necrosis factor-alpha rceptor (p55/p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther 288:945-950, 1999.
103. Blouin RA, Farrell GC, Ioannides C, Renton K, Watlington CO: Impact of diseases on detoxification. J Biochem Mol Toxicol 13:215-218, 1999.
104. Watson AM, Poloyac SM, Howard G, Blouin RA: The effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos 27 (6):695-700, 1999.
105. Lu M, Poloyac SM, McNamara PJ, Blouin RA: The effect of pregnenolone 16 alpha-carbonitrile on the pharmacokinetics and metabolism of dapsone in rats. J Pharm & Pharmacol 51:803-810, 1999.
106. Rockich K, Blouin RA: The effect of the acute phase response on the pharmacokinetics of chlorzoxazone and cytochrome P450 2E1 in vitro activity in rats. Drug Metab Dispos 27:1074-1077, 1999.
107. Rockich K, Hatton J, Kryscio D, Young B, Blouin RA: Effect of intravenous infusion of rhIGF-1 and daily subcutaneous rhGH and IGFBP-3 levels in brain injury. Pharmacotherapy 19:1432-1436, 1999.
108. Poloyac SM, Tosheva RT, Shedlofsky SI, Blouin RA: The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans. Clin Pharmacol Ther 66:554-562, 1999
109. Poloyac SM, Perez-Rivera AA, Scheff S, Blouin RA: Tissue specific alterations in the 6-hydroxylation of chlorzoxazone following traumatic brain injury in the rat. Drug Metab Dispos 29:296-298, 2001.
110. Oakley GG, Roe AL, Blouin RA, Twaroski TP, Ganguly TC, Vore M, Lehmler H-J, Robertson LW: 2,4,4’-Trichlorobiphenyl increases STAT5 transcriptional activity. Mol Carcinog 30:199-208, 2001.
111. Warren GW, Van Ess P, Watson AM, Mattson MP, Blouin RA: Cytochrome P450 and antioxidant activity in interleukin-6 knockout mice after induction of the acute phase response. J Interferon Cytokine Res 21:821-826, 2001.
112. Roe AL, Poloyac SM, Howard G, Shedlofsky SI, Blouin RA: The effect of endotoxin on hepatic nuclear factor 1 nuclear protein binding: potential implications on CYP2E1 expression in the rat. J Pharm Pharmacol 53:1365-1371, 2001.
113. Van Ess PJ, Pedersen WA, Culmsee C, Rowley D, Mattson MP, Blouin RA: Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurochem 80: 571-578, 2002.
114. Van Ess PJ, Mattson MP, Blouin RA: Enhanced induction of cytochrome P450 enzymes and CAR binding in the TNF (p55-/-/p75-/-) double receptor knockout mice following Phenobarbital treatment. J Pharmacol Exp Ther 300: 824-830, 2002.
115. Van Ess PJ, Poloyac SM, Mattson MP, Blouin RA: Blunted induction of hepatic CYP in TNF (p55-/-/p75-/-) double receptor knockout mice following clofibrate treatment. Pharm Res 19:709-713, 2002.
116. Rockich KR, Tosheva R, Cunningham C, Goeger D, Blouin RA, Shedlofsky S: The effect of endotoxin administration on three putative CYP3A markers in human subjects. (Submitted).